Publication date: Dec 26, 2024
The use of antibody titers against SARS-CoV-2, as a method of estimating subsequent infection following infection or vaccination, is unclear. Here, we investigate whether specific levels of antibodies, as markers of adaptive immunity, can serve to estimate the risk of symptomatic SARS-CoV-2 (re-) infection. In this real-world study, laboratory data from individuals tested for SARS-CoV-2 antibodies under routine clinical conditions were linked through tokenization to a United States medical insurance claims database to determine the risk of symptomatic/severe SARS-CoV-2 infection outcomes. Antibody titer levels were determined using the Elecsys Anti-SARS-CoV-2 S assay. Study outcomes included the first symptomatic SARS-CoV-2 infection (per ICD-10 diagnostic codes, occurring ≥ 7 days post-antibody titer test), and severe SARS-CoV-2 infection, characterized by adverse outcomes including hospitalization, intensive care unit admission, intubation, mechanical ventilation, or death within 30 days of infection. All outcomes were assessed for 12 months following antibody measurement. Hazard ratios of subsequent symptomatic and severe infections were estimated using Cox regression with inverse probability weighting. Of 268,844 individuals with antibody data (April 2021-June 2022), those with levels ≥ 0. 8 to
Concepts | Keywords |
---|---|
Antibodies | COVID-19 |
Hospitalization | Immune response |
June | Immunity |
Real-world data | |
Risk estimate | |
SARS-CoV-2 | |
Spike antibody titer |
Semantics
Type | Source | Name |
---|---|---|
disease | MESH | Re-infection |
disease | MESH | infection |
disease | MESH | SARS-CoV-2 infection |
pathway | REACTOME | SARS-CoV-2 Infection |
disease | IDO | assay |
disease | MESH | death |
disease | IDO | immune response |